Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (39)
April 14, 2003
- Maurer's Healthcare Insight (Special)
March 24, 2003
- Maurer's Healthcare Insight (Special)
March 17, 2003
- Maurer's Healthcare Insight (38)
February 17, 2003
- Maurer's Healthcare Insight (37)
January 20, 2003
- Maurer's Healthcare Insight (36)
December 2, 2002
- Maurer's Healthcare Insight (35)
November 11, 2002
- Maurer's Healthcare Insight (33)
September 2, 2002
- Maurer's Healthcare Insight (32)
August 5, 2002
- Maurer's Healthcare Insight (31)
July 22, 2002
- Maurer's Healthcare Insight (30)
July 1, 2002
- Maurer's Healthcare Insight (29)
June 3, 2002
- Maurer's Healthcare Insight (28)
May 20, 2002
- Maurer's Healthcare Insight (27)
April 29, 2002
- Maurer's Healthcare Insight (27)
April 15, 2002
- Maurer's Healthcare Insight (26)
March 18, 2002
- Maurer's Healthcare Insight (25)
February 25, 2002
- Maurer's Healthcare Insight (20)
September 17, 2001
- Maurer's Healthcare Insight (19)
September 3, 2001
- Maurer's Healthcare Insight(18)
August 6, 2001
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…